Gyros Protein Technologies
  • IMMUNOASSAY SOLUTIONS
  • PEPTIDE SYNTHESIZERS
  • CORPORATE
  • Interests
    • COVID-19
    • Immunoassays
    • Cell & Gene Therapy
    • Vaccines
  • Products
    • Gyrolab Systems
      • Gyrolab xPlore
      • Gyrolab xPand
    • Consumables
      • Gyrolab CDs
      • Gyrolab Kits and Solutions
      • Buffers and Accessories
    • Gyrolab Assay Protocols
    • Gyrolab Software
    • Gyrolab Custom Assay Services
      • Biomolecule Labeling 
      • Custom Assay Development 
      • Custom Kit Development 
    • Service and Support
  • Applications
    • Pre-clinical
      • Pharmacokinetics (PK)/Toxicokinetics (TK)
      • Biomarker Monitoring & Pharmacodynamics (PD)
      • Affinity
      • Immunogenicity
    • Clinical
      • Pharmacokinetics (PK)/Toxicokinetics (TK)
      • Biomarker Monitoring & Pharmacodynamics (PD)
      • Affinity
      • Immunogenicity
    • Bioprocess
      • Impurity Testing
      • Product Titer Quantification
      • Affinity
  • Resources
    • Gyrolab User Zone
    • SpinBlog
    • Gyrolab Assay Protocols
    • References
    • Brochures
    • Product Information Sheets
    • Application Notes
    • Application Reports
    • Technical Notes
    • Case Studies
    • Posters
    • Seminars
    • Webinars
    • White Papers
    • Certificate of Analysis
    • Instructions for Use
    • MSDS
  • About Us
    • Why Gyrolab
    • Technology
    • Installations Worldwide
    • CRO Partners
    • History
    • News
  • Contact
    • Sales and Support by Region
    • Ordering Information
    • Order Placement
    • Terms & Conditions
Share
  • Share on Facebook
  • Tweet
  • Share on Google+
  • Share on LinkedIn
  • Send email
Subscribe

Gyrolab Spin Blog: biosimilars

May 11, 2015 11:39:00 AM

Biosimilars

  • Tweet

biosimilars_imagePatently a great idea

Gyros is participating at Informa's 12th Annual Biosimilars conference next week (May 18–20) in Berlin. The conference gives an overview of the current regulatory, scientific and market access perspectives for biosimilars.

Read More
0 Comments Click here to read/write comments

Topics: Microsampling, Biosimilars


All posts

Recent Posts

Related Topic

  • Pharmacokinetics (15)
  • Assay Development (12)
  • Microsampling (9)
  • Immunoassay (8)
  • ADA (5)
  • Assay Automation (5)
  • Gyrolab system (5)
  • Matrix (5)
  • Vaccine (5)
  • Regulated bioanalysis (4)
  • Serial sampling (4)
  • Affinity (3)
  • Biomarkers (3)
  • Bioprocess (3)
  • Gene therapy (3)
  • HCP (3)
  • Toxicokinetics (3)
  • ADME (2)
  • Affinity determination (2)
  • Antibody-Drug Conjugate (2)
  • Clinical trial (2)
  • Immunogenicity (2)
  • Impurity testing (2)
  • Affinity in solution (1)
  • Autoantibodies (1)
  • Biodistribution (1)
  • Biosimilars (1)
  • COVID-19 (1)
  • CRO transfer (1)
  • Clinical samples (1)
  • Crohn's disease (1)
  • Diabetes (1)
  • Diabetes biomarkers (1)
  • GLP-1 (1)
  • Gyrolab xPand (1)
  • Gyros (1)
  • Host Cell Proteins (1)
  • Immunoassay platform (1)
  • Infectious Diseases (1)
  • Multiplexing (1)
  • Obesity (1)
  • Phase III studies (1)
  • Preclinical studies (1)
  • Publications (1)
  • Symphony peptide synthesizer (1)
  • Toxicology assays (1)
  • Ulcerative colitis (1)
  • solid-phase peptide synthesis (1)
see all
Peptide-synthesizers.png

Get in touch

+46 18 566 300

 

Newsletter sign up!

FacebookLinkedin
  • gyrosproteintechnologies.com
  • Site Use Terms
  • Privacy Policy
  • Legal Notice
Copyright © 2021 Gyros Protein Technologies AB All Rights Reserved.